Placebo spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Placebo spray and moxifloxacin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effects of Sativex on ECG
Conditions
Effects of Sativex on ECG
Trial Timeline
Dec 1, 2007 → Jun 1, 2008
NCT ID
NCT01322139About Placebo spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Placebo spray and moxifloxacin
Placebo spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Sativex spray and oral moxifloxacin placebo + Placebo spray and moxifloxacin is a phase 1 stage product being developed by Jazz Pharmaceuticals for Effects of Sativex on ECG. The current trial status is completed. This product is registered under clinical trial identifier NCT01322139. Target conditions include Effects of Sativex on ECG.
What happened to similar drugs?
1 of 2 similar drugs in Effects of Sativex on ECG were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01322139 | Phase 1 | Completed |
Competing Products
10 competing products in Effects of Sativex on ECG
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment C | Daiichi Sankyo | Phase 1 | 29 |
| Budesonide Nasal | Johnson & Johnson | Approved | 47 |
| SHR-1603 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Albuterol Sulfate + Nicardipine Hydrochloride + Dobutamine Hydrochloride + Phenylephrine Hydrochloride + Verapamil Hydrochloride + Phentolamine Mesylate + Placebo | AstraZeneca | Phase 1 | 21 |
| daptomycin | Merck | Phase 3 | 40 |
| Cyclosporine & Cellcept + Prograf & Cellcept + Low Dose CNI (Cyclosporine or FK) and Cellcept + Rapamune and Cellcept | Roche | Phase 1/2 | 32 |
| Evolocumab | Amgen | Phase 1 | 25 |
| GS-0976 + Placebo | Gilead Sciences | Phase 1 | 29 |
| Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine + Pneumococcal protein vaccine | Sanofi | Phase 1 | 29 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 23 |